Early Clinical Trial Supports MASL as a Targeted Oral Cancer Treatment

Early clinical trial supports MASL as a targeted oral cancer treatment

Rowan University and Sentrimed, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) funded clinical trial evaluating MASL in patients with oral squamous cell carcinoma (OSCC).

Rowan University and Sentrimed Announce Phase 1 Clinical Trial Results Demonstrating Potential of MASL to Inhibit Oral Cancer Cell Migration and Viability

Rowan University and Sentrimed®, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) funded clinical trial evaluating MASL® in patients with oral squamous cell carcinoma (OSCC). The Company’s lead product candidate, MASL, is a novel lectin-based therapeutic licensed from Rowan University.